A surge in demand for GLP-1 medications landed tirzepatide on the FDAs official drug shortage list in December 2022
The only area where it gained some interest was as a means to help terminate hypoglycaemia in schizophrenic patients given insulin shock therapy (figure 13)
And will these medications actually work if your metabolism is already sluggish

Key Findings: Large human studies across multiple countries have not found increased thyroid cancer rates in GLP-1 users The FDA warning applies to medullary thyroid carcinoma (MTC)only 3-4% of all thyroid cancers The warning exists because rodents developed C-cell tumors, but humans and rodents differ biologically Some studies show associations, but these are explained by detection bias (more monitoring = finding pre-existing nodules) The Clayman Thyroid Center (2,000+ thyroid cancer patients/year) has not seen an MTC pattern linked to GLP-1 use (or for that matter any other thyroid malignancy) Clinical Recommendations: Patients with MTC history or MEN2 should not take GLP-1 receptor agonists Patients with common thyroid cancers (papillary, follicular, Hrthle cell) should not assume GLP-1 caused them or will have an effect upon them Decisions should be individualized, weighing metabolic benefits against theoretical concerns GLP-1 therapy does not require additional thyroid monitoring Quick Reference for Clinicians Understanding the Question What Medications Are We Discussing

Step 1: Test your hormone levels Dont guess
the dosing depends on the ailment being treated, the weight of the dog, and response to treatment